tradingkey.logo

Incyte Corp Says Phase 3 True-Pn1 Study Meets All Primary And Key Secondary Endpoints

ReutersMar 8, 2025 2:08 PM

- Incyte Corp INCY.O:

  • INCYTE ANNOUNCES RESULTS OF PHASE 3 CLINICAL TRIALS EVALUATING RUXOLITINIB CREAM 1.5% (OPZELURA®) IN PATIENTS WITH PRURIGO NODULARIS (PN) AT 2025 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING

  • INCYTE CORP - PHASE 3 TRUE-PN1 STUDY MEETS ALL PRIMARY AND KEY SECONDARY ENDPOINTS

  • INCYTE - TOPLINE DATA FROM SEPARATE PHASE 3 STUDY, TRUE-PN2, SHOWED THAT PRIMARY ENDPOINT DID NOT REACH STATISTICAL SIGNIFICANCE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI